Sofinnova Partners and NVIDIA look to accelerate European life sciences startups

2
Photo: Pete Linforth/Pixabay

Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, has announced a collaboration with NVIDIA to support its portfolio of life sciences startups. The collaboration delivers graphics processing unit (GPU) credits to select Sofinnova portfolio companies, effectively giving access to the same computational firepower used by tech titans in Silicon Valley.

With increasing demand for compute resources driven by AI, Sofinnova’s portfolio companies will be able to access NVIDIA Blackwell and other NVIDIA architecture GPUs via  NVIDIA DGX Cloud Lepton, an AI platform and marketplace connecting developers to global AI infrastructure.

BioCorteX, Bioptimus, Cure51 and Latent Labs—four of Europe’s most promising digital medicine startups—will gain access to computing resources through DGX Cloud Lepton, enabling them to process biological data sets and run computational models that would have taken months, completing them in days.

Cure51, a pioneer in decoding the biology of exceptional cancer survivors, tested NVIDIA Parabricks, a GPU-accelerated genomics toolkit, and achieved up to 17x faster processing with NVIDIA H100 GPUs and more than double cost savings with NVIDIA L4 GPUs compared to their CPU baseline—accelerating their ability to analyse complex genomic data and scale their survivor-based insights.

“This collaboration supercharges computation for life sciences innovation,” said Antoine Papiernik, chairman and managing partner at Sofinnova Partners.

“The convergence of biology, AI, computation, and data isn’t just our investment thesis—it’s the defining battleground of the next decade. From our digital medicine strategy to our own proprietary AI platform Sofinnova.ai, we recognize the transformative potential of AI across our entire domain. By securing access to NVIDIA’s infrastructure, we’re not just funding companies; we’re empowering them with the computational backbone needed to outperform incumbents and redefine what’s possible in drug discovery, precision medicine, and scalable solutions that address both human health and sustainability.”

+ posts

Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.